Ultragenyx Pharmaceutical Inc and GeneTx Biotherapeutics LLC GTX-102 Interim Data and Program Update Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Ultragenyx GTX-102 for Angelman syndrome interim data and program update Conference Call. (Operator Instructions)
It is now my pleasure to turn today call over to Joshua Higa, Executive Director and Head of Investor Relations. You may begin.
Thank you. We issued a press release and posted slides that detail this interim data and program update, which you can find on our website at ir.ultragenyx.com.
Joining me on this call from the company are Emil Kakkis, Chief Executive Officer and President; Camille Bedrosian, Chief Medical Officer; Scott Stromatt, Chief Medical Officer of Neurology; Mardi Dier, Chief Financial Officer; and Tom Kassberg, Chief Business Officer.
I'm also pleased to be joined on this call by 2 investigators on our study: Dr. Erick Sell, Associate Professor Neurology at Children's Hospital of Eastern Ontario in Ottawa, Canada; and Dr. Elizabeth Berry-Kravis,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |